A public-source reconstruction of the Orviglance FDA evidence pathway, examining why statistically positive Phase 3 results did not, by themselves, establish decision-ready regulatory evidence. The analysis traces how reader interpretation, endpoint construction, and evidentiary assumptions shape the transition from scientific observation to regulatory decision support.
Most ALD mRNA programs don’t fail on biology—they fail on decision ambiguity: unclear success definitions, CNS “signal” without thresholds, and CMC variability that quietly changes what a “dose” means. In this case study, Method2Model turns a dual-platform ABCD1 mRNA concept (LNP + EV, Peripheral-First → CNS) into a stage-locked decision engine: a full A–G architecture, a formal formula pack, and an executable Stage-3 core (mouse branch) with verification evidence. The result is decision-grade Go/No-Go/Pivot governance—so teams can move faster with fewer reruns, fewer false conclusions, and fewer late-stage surprises.
This case study documents an end-to-end, stage-locked in-vitro screening system for sOMF exposure in 5HN and CD8 models. The work combines a complete Stage-1 execution and governance architecture (protocol, QC, audit artifacts) with a Stage-2 mathematical formalization that removes ambiguity from normalization, drift handling, evaluability constraints, and tiered selection outcomes. The result is an implementation-ready decision framework that is deterministic, traceable, and robust to common early-screening failure modes.
Equilibrium Window of Health is a stage-locked, event-aware early-drift monitoring core designed for real-world longitudinal data. It infers a patient-specific equilibrium baseline, tracks a five-axis latent state with uncertainty, and separates chronic drift from recorded acute events via transparent attribution tags. Built with a formal I/O contract and QC artifacts, it produces reproducible, audit-friendly outputs across cheap/mixed/full measurement regimes.
Used when: early drift detection, longitudinal biomarkers, prevention decision thresholds.. A lightweight, PB-inspired dynamic health model demo for small longitudinal biomarker series. It builds a personal baseline, detects early drift in log-space, and offers an optional 4D “prevention core” to visualize simple intervention effects—focusing on clarity, transparency, and reproducibility rather than clinical deployment.
